AbbVie Inc. has released a preliminary report on July 3, 2024, detailing the expected financial results for the second quarter of 2024. The report includes an acquired IPR&D and milestones expense of $937 million on a pre-tax basis, which is anticipated to negatively impact GAAP and non-GAAP diluted earnings per share by $0.52. The results for the quarter ending June 30, 2024, are not yet finalized and are subject to financial statement closing procedures. AbbVie has updated its full-year 2024 adjusted diluted earnings per share guidance to a range of $10.61 to $10.81, including the impact of the second quarter's acquired IPR&D and milestones expense. The second quarter's adjusted diluted earnings per share guidance is set between $2.53 and $2.57. The company has previously announced that its adjusted diluted earnings per share guidance for 2024, announced on April 26, 2024, did not include the impact of any acquired IPR&D and milestones expense beyond the first quarter. AbbVie's forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those projected.

AbbVie Inc. has released a preliminary report on July 3, 2024, detailing the expected financial results for the second quarter of 2024. The report includes an acquired IPR&D and milestones expense of $937 million on a pre-tax basis, which is anticipated to negatively impact GAAP and non-GAAP diluted earnings per share by $0.52. The results for the quarter ending June 30, 2024, are not yet finalized and are subject to financial statement closing procedures. AbbVie has updated its full-year 2024 adjusted diluted earnings per share guidance to a range of $10.61 to $10.81, including the impact of the second quarter's acquired IPR&D and milestones expense. The second quarter's adjusted diluted earnings per share guidance is set between $2.53 and $2.57. The company has previously announced that its adjusted diluted earnings per share guidance for 2024, announced on April 26, 2024, did not include the impact of any acquired IPR&D and milestones expense beyond the first quarter. AbbVie's forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those projected.